A well-funded bispecific-antibody oncology underdog with a single survival-data gate in 2026 that could unlock a 2027 launch—or reset the entire equity story.
Overview
Compass Therapeutics (CMPX) is a Boston-based, clinical-stage oncology biopharma developing proprietary monoclonal and bispecific antibodies aimed at reprogramming the tumor microenvironment—specifically the intersection of angiogenesis, immune suppression, and tumor growth. The company is pre-commercial and does not generate recurring product revenue; funding is primarily from capital raises with modest interest income and occasional licensing-related revenue. FY2025 reflected an intensifying late-stage posture: net loss widened to ~$66.5M as R&D and manufacturing spend increased to support pivotal development, while the balance sheet strengthened materially to ~$209M in cash/marketable securities, which management expects to fund operations into 2028. The pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific in Phase 2/3 for second-line biliary tract cancer, with a statistically significant ORR advantage versus paclitaxel (17.1% vs 5.3%)—positioning the company at a pivotal inflection. Other programs provide optionality: CTX-8371 (PD-1 x PD-L1) aims to unlock responses in checkpoint-refractory patients via a differentiated mechanism involving PD-1 receptor cleavage; CTX-10726 (PD-1 x VEGF-A) is entering Phase 1 with claims of superior preclinical activity versus ivonescimab-like comparators; and CTX-471 is a differentiated CD137 agonist designed to maximize immune activation while reducing hepatotoxicity risk. The investment case is dominated by the April 2026 OS/PFS readout for tovecimig, which will determine regulatory trajectory and commercial feasibility.